Earlier this month, Josep M. Llibre, M.D., and Benjamin Young, M.D., Ph.D., and thousands of HIV experts attended the 21st Conference on Retroviruses and Opportunistic Infections (CROI), in Boston, Massachusetts. The two doctors met over a tasty hamburger lunch to compare their thoughts and views on the top studies from the conference. Here are the top take-home messages they felt came from CROI 2014.
Table of Contents
- Initial HIV Treatment With a 2-Drug, Nuke-Sparing Regimen Falls Short
- Raltegravir Superior to Boosted PIs as First-Line Treatment
- STRATEGY: Switches to Stribild From NNRTI or Boosted PI Work
- Update on GSK744 and Monthly HIV Treatment or PrEP
- The Fast-Paced Evolution of Hepatitis C Treatment and Cures
- Safer Sex Without a Condom: The PARTNER Study
- Very Early Treatment Benefits and Possible HIV Eradication
Josep M. Llibre, M.D., is in the HIV Unit of the "Lluita contra la SIDA" Foundation at University Hospital Germans Trias i Pujol, Universitat Autònoma de Barcelona, Badalona, Spain. Dr. Llibre has received funding for research or payment for conferences or participation on advisory boards from Abbott, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead Sciences, Janssen-Cilag, Merck Sharp & Dohme, and ViiV Healthcare.
Benjamin Young, M.D., Ph.D., is vice president and chief medical officer of the International Association of Providers of AIDS Care based in Washington, D.C., and an adjunct professor at the Josef Korbel School of International Studies at the University of Denver. Dr. Young has received consulting or speaking fees from Bristol-Myers Squibb, Cerner Corporation, Gilead Sciences, GlaxoSmithKline, Merck & Co., Monogram Biosciences, and ViiV Healthcare. He has received research funding from Bristol-Myers Squibb Company, Cerner Corporation, Gilead Sciences, GlaxoSmithKline, Merck & Co., and ViiV Healthcare.